Outcomes of adults hospitalised with severe influenza

Thorax

Volumn 65, Issue 6, 2010, Pages 510-515

  Lee, N ^a   Choi, K W ^a   Chan, Paul K S ^b   Hui, D S C ^a   Lui, G C Y ^a   Wong, B C K ^a   Wong, R Y K ^a   Sin, W Y ^a   Hui, W M ^a   Ngai, K L K ^b   Cockram, C S ^a   Lai, R W M ^b   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OSELTAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENERAL HOSPITAL; HOSPITAL DISCHARGE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUTATION; NASOPHARYNGEAL ASPIRATION; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; SEPSIS; SEQUENCE ANALYSIS; SURVIVAL; VIRUS DETECTION; VIRUS ISOLATION; AGE; CLINICAL TRIAL; EPIDEMIOLOGY; HONG KONG; HOSPITALIZATION; INFLUENZA, HUMAN; LENGTH OF STAY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; SEASON; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; HONG KONG; HOSPITALIZATION; HOSPITALS, GENERAL; HUMANS; INFLUENZA, HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PROGNOSIS; RESPIRATION, ARTIFICIAL; SEASONS; SEX FACTORS; TREATMENT OUTCOME;

EID: 77953690216     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.130799     Document Type: Article

References (53)

1. World Health Organization (WHO). Fact sheet on influenza. http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 1 Feb 2010).
2. Fiore AE, Shay DK, Broder K, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-60.
3. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
5. Schanzer DL, Tam TW, Langley JM, et al. Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect 2007;135:1109-16.
6. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008;121:258-64.
7. Wong CM, Yang L, Chan KP, et al. Influenza-associated hospitalisation in a subtropical city. PLoS Med 2006;3:e121.
8. Yap FH, Ho PL, Lam KF, et al. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol 2004;73:617-23.
9. Wong CM, Chan KP, Hedley AJ, et al. Influenza-associated mortality in Hong Kong. Clin Infect Dis 2004;39:1611-17.
10. WHO. Pandemic H1N1. 2009. http://www.who.int/csr/disease/swineflu/en/ index.html (accessed 1 Feb 2010).
11. Dawood FS, Jain S, Finelli L, et al. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15.
12. Jain S, Kamimoto L, Bramley AM, et al. the 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44.
13. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;361:680-9.
14. Kumar A, Zarychanski R, Pinto R, et al. for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872-9.
15. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007;167:354-60.
16. Call SA, Vollenweider MA, Hornung CA, et al. Does this patient have influenza? JAMA 2005;293:987-97.
17. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139:321-9.
18. McGeer A, Green KA, Plevneshi A, et al. Toronto invasive bacterial diseases network. Antiviral therapy and outcomes of influenza requiring hospitalisation in Ontario, Canada. Clin Infect Dis 2007;45:1568-75.
19. Lee N, Chan PKS, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007;12:501-8. (Pubitemid 47041148)
20. Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 2007;195:1029-37.
21. Babcock HM, Merz LR, Dubberke ER, et al. Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:921-6.
22. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003;8:183-90.
23. Harper SA, Bradley JS, Englund JA, et al. Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1003-32.
24. McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis 2009;48 (Suppl 1):S14-19.
25. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;200:492-500.
26. Lee N, Wong CK, Chan PK, et al. Hypercytokinemia and hyperactivation of phosphop38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007;45:723-31.
27. Hospital Authority, Hong Kong SAR. Influenza page. HA operational plan on laboratory testing for human influenza infection. 2005. http://www3.ha.org.hk/ idctc (accessed 30 Jun 2008).
28. Hospital Authority, Hong Kong SAR. Influenza page. Fact Sheet on antiviral therapy against influenza. Hospital Authority, Hong Kong SAR. Version 2005. http://www3.ha.org.hk/idctc (accessed 30 Jun 2008).
29. Centre for Health Protection, Hong Kong SAR. Influenza page. http://www.chp.gov.hk/en/dns-submenu/10/26/44.html. (accessed 30 Sep 2009).
30. Cheng PK, Leung TW, Ho EC, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009;15:966-8.
31. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009;360:953-6.
32. PASW Statistics software, version 17.0 http://support.spss.com/ ProductsExt/Statistics/Documentation/17.0.2/index.html
33. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
34. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.
35. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001;161:212-17. (Pubitemid 32102388)
36. Li G, Yilmaz M, Kojicic M, et al. Outcome of critically ill patients with influenza virus infection. J Clin Virol 2009;46:275-8.
37. Ho YC, Wang JL, Wang JT, et al. Prognostic factors for fatal adult influenza pneumonia. J Infect 2009;58:439-45.
38. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007;44:964-7.
39. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009;4:e6051.
40. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008;372:744-9.
41. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009;48:1639-46.
42. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Atlanta: Centers for Disease Control and Prevention. http://www.cdc.gov/h1n1flu/ recommendations.htm) (accessed 1 Feb 2010).
43. Hassan K, McGeer A, Green KA, et al. Antiviral therapy improves outcomes of influenza infections in patients requiring admission to intensive care. 49th ICAAC, 2009, presentation V-537.
44. Rahman M, Vandermause MF, Kieke BA, et al. Performance of Binax NOW Flu A and B and direct fluorescent assay in comparison with a composite of viral culture or reverse transcription polymerase chain reaction for detection of influenza infection during the 2006 to 2007 season. Diagn Microbiol Infect Dis 2008;62:162-6.
45. Chan KH, Peiris JS, Lim W, et al. Comparison of nasopharyngeal flocked swabs and aspirates for rapid diagnosis of respiratory viruses in children. J Clin Virol 2008;42:65-9.
46. Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (Swine) influenza A/H1N1. Clin Infect Dis 2009;49:1090-3.
47. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009;58:1071-4.
48. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS guidelines for CAP in adults. Clin Infect Dis 2007;44:S27-72.
49. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005;192:249-57.
50. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004;190:519-26.
51. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007;12(4 Pt B):603-16. (Pubitemid 47235503)
52. Dharan NJ, Gubareva LV, Meyer JJ, et al. Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009;301:1034-41.
53. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48 (Suppl 1):S3-13.